CSL Saham

CSL Margin FCF

Delisted·19 Jun 2026

Margin Arus Kas Bebas dari CSL (CSL.AX) pada 16 Agu 2026 adalah 16,47 %. Tahun sebelumnya, Margin Arus Kas Bebas adalah 10,18 % — perubahan sebesar 61,89% (lebih tinggi).

Margin FCF

16,47 %

YoY

61,89%

Terakhir Diperbarui:

Margin Arus Kas Bebas dari CSL adalah 2026 16,47 % . Margin Arus Kas Bebas dari CSL adalah 2025 10,18 % . Menurun 61,89% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

CSL Analisis saham

Apa yang dilakukan CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham CSL

Margin Arus Kas Bebas CSL adalah 16,47 % pada tahun 2026.

Margin Arus Kas Bebas dari CSL berubah dari 10,18 % menjadi 16,47 %, mewakili perubahan 61,89%. Nilainya lebih tinggi daripada tahun sebelumnya.

Di Eulerpool Anda dapat menemukan perkembangan historis lengkap Margin Arus Kas Bebas CSL sejak 2006 – dengan nilai tahunan, bagan, dan analisis detail.

Margin FCF mengukur persentase pendapatan yang dikonversi menjadi arus kas bebas. Ini menunjukkan seberapa efisien perusahaan menghasilkan kas dari operasinya.

Nilai '' yang 'baik' bervariasi menurut industri dan tahap perusahaan. Di Eulerpool, Anda dapat membandingkan CSL Margin Arus Kas Bebas dengan pesaing sektor dan rata-rata industri untuk menilai apakah menarik.

Untuk mengevaluasi Margin Arus Kas Bebas, sangat penting untuk membandingkannya dengan perusahaan sejenis di industri dan sektor yang sama. Di Eulerpool, Anda dapat menemukan perbandingan industri langsung untuk Margin Arus Kas Bebas.

Access this data via the Eulerpool API

Margin — CSL

Semua Metrik Kunci — CSL